Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.62 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.62 |
| ▸ | SMO | Q99835 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 2/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2624739 | 0.90 | KDM4E (0.55) | KDM4EMAPK10SMOMAPTALDH1A1 | |
| SCHEMBL2740177 | 0.85 | ALDH1A1 (0.75) | KDM4EMAPTALDH1A1LMNAHPGD | |
| SCHEMBL2624689 | 0.84 | SMO (0.60) | KDM4EMAPK10SMOMAPTALDH1A1 | |
| SCHEMBL18993820 | 0.84 | SMO (0.49) | KDM4EMAPK10SMOMAPTALDH1A1 | |
| SCHEMBL2624506 | 0.82 | TLR9 (0.63) | KDM4EMAPTALDH1A1LMNAHPGD | |
| SCHEMBL14886519 | 0.81 | SIRT1 (0.54) | KDM4EMAPTALDH1A1LMNAHPGD | |
| SCHEMBL2740427 | 0.79 | SIRT1 (0.68) | KDM4EMAPTALDH1A1LMNAHPGD | |
| SCHEMBL2624512 | 0.79 | PDCD1 (0.51) | KDM4EMAPK10MAPTALDH1A1LMNA | |
| SCHEMBL24715798 | 0.79 | CASP3 (0.61) | KDM4EMAPK10SMOMAPTALDH1A1 | |
| SCHEMBL10756796 | 0.79 | TLR9 (0.64) | KDM4EMAPK10SMOMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10383837-B2 | Compositions and methods for modulating metabolic pathways | NUSIRT SCIENCES, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190224152-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | NUMETA SCIENCES, INC. | 2019-07-25 | — | — | US | disclosed |
| US-9855235-B2 | Compositions and methods for modulating metabolic pathways | NUSIRT SCIENCES, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170312240-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | NUMETA SCIENCES, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170312240-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | NUMETA SCIENCES, INC. | 2017-11-02 | — | — | US | disclosed |
| US-9682053-B2 | Compositions and methods for modulating metabolic pathways | NUSIRT SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682053-B2 | Compositions and methods for modulating metabolic pathways | NUSIRT SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9585907-B2 | Methods and compositions for modulating Tau levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2017-03-07 | — | — | US | disclosed |
| US-9585907-B2 | Methods and compositions for modulating Tau levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160338983-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | NUMETA SCIENCES, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007019346-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019417-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019416-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019345-A1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRTIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRT2, SIRT1, SIRT3 | KDM4E 1227/4885MAPK10 1595/4885SMO 2239/4885 |
| US-20190224152-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | PC, HADHB, ACACB | KDM4E 777/4885MAPK10 1781/4885SMO 2320/4885 |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRT1, SIRT3, SIRT2 | KDM4E 540/4885MAPK10 873/4885SMO 2537/4885 |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRT2, SIRT1, SIRT3 | KDM4E 1399/4885MAPK10 2337/4885SMO 2047/4885 |
| US-20170312240-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | PC, HADHB, ACACB | KDM4E 777/4885MAPK10 1781/4885SMO 2320/4885 |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | KDM4E 1388/4885MAPK10 892/4885SMO 2542/4885 |
| US-10383837-B2 | Compositions and methods for modulating metabolic pathways | PC, HADHB, ACACB | KDM4E 777/4885MAPK10 1781/4885SMO 2320/4885 |
| US-20160338983-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | PC, HADHB, ACACB | KDM4E 777/4885MAPK10 1781/4885SMO 2320/4885 |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | KDM4E 1388/4885MAPK10 892/4885SMO 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.